

## NETWORK Notification

Notice Date: January 1, 2024

To: CareSource Providers

From: CareSource

Subject: Avalon Q3 2023 Quarterly Policy Updates

## **Summary**

CareSource has partnered with Avalon Healthcare Solutions for laboratory benefits management (LBM), including routine testing management (RTM), a post-service pre-payment clinical claim editing program for routine lab testing.

The RTM program is based on ensuring compliance with the lab policies located on Avalon's website.

This notification is intended to provide you notification of changes to the policies listed below. The policies appear on Avalon website upon their effective dates.

## **Policies**

Policy Name	Plans	Effective Date
G2002 Cervical Cancer Screening: Effective Date: 03/01/2024	Ohio Dual Special Needs (D-SNP)	03/01/2024
G2007 Prostate Biopsy Specimen Analysis: Effective Date: 3/01/2024	Ohio Dual Special Needs (D-SNP)	03/01/2024
G2036 Hepatitis Testing: Effective Date: 03/01/2024	Ohio Dual Special Needs (D-SNP)	03/01/2024
G2043 Celiac Disease Testing: Effective Date: 03/01/2024	Ohio Dual Special Needs (D-SNP)	03/01/2024
G2048 Biochemical Markers of Alzheimer Disease and Dementia: Effective Date: 03/01/2024	Ohio Dual Special Needs (D-SNP)	03/01/2024
G2051 Bone Turnover Markers Testing: Effective Date: 03/01/2024	Ohio Dual Special Needs (D-SNP)	03/01/2024
G2059 Epithelial Cell Cytology in Breast Cancer Risk Assessment: Effective Date: 03/01/2024	Ohio Dual Special Needs (D-SNP)	03/01/2024
G2060 Fecal Analysis in The Diagnosis of Intestinal Dysbiosis and Fecal Microbiota Transplant Testing: Effective Date: 03/01/2024	Ohio Dual Special Needs (D-SNP)	03/01/2024
G2061 Fecal Calprotectin Testing: Effective Date: 03/01/2024	Ohio Dual Special Needs (D-SNP)	03/01/2024

G2098 Immune Cell Function Assay: Effective Date: 03/01/2024	Ohio Dual Special Needs (D-SNP)	03/01/2024
G2100 In Vitro Chemoresistance and Chemosensitivity Assays	Ohio Dual Special Needs (D-SNP)	03/01/2024
G2105 Immunopharmacologic Monitoring of Therapeutic Serum Antibodies: Effective Date: 03/01/2024	Ohio Dual Special Needs (D-SNP)	03/01/2024
G2107 Measurement of Thromboxane Metabolites for ASA Resistance: Effective Date: 03/01/2024	Ohio Dual Special Needs (D-SNP)	03/01/2024
G2110 Serum Testing for Hepatic Fibrosis in the Evaluation and Monitoring of Chronic Liver Disease: Effective Date: 03/01/2024	Ohio Dual Special Needs (D-SNP)	03/01/2024
G2115 Metabolite Markers for Thiopurines Testing: Effective Date: 03/01/2024	Ohio Dual Special Needs (D-SNP)	03/01/2024
G2119 Diagnostic Testing of Influenza: Effective Date: 03/01/2024	Ohio Dual Special Needs (D-SNP)	03/01/2024
G2121 Laboratory Testing for the Diagnosis of Inflammatory Bowel Disease: Effective Date: 03/01/2024	Ohio Dual Special Needs (D-SNP)	03/01/2024
G2123 Serum Biomarker Testing for Multiple Sclerosis and Related Neurologic Diseases: Effective Date: 03/01/2024	Ohio Dual Special Needs (D-SNP)	03/01/2024
G2150 Biomarkers for Myocardial Infarction and Chronic Heart Failure: Effective Date: 03/01/2024	Ohio Dual Special Needs (D-SNP)	03/01/2024
G2157 Diagnostic Testing of Common Sexually Transmitted Infections: Effective Date: 03/01/2024	Ohio Dual Special Needs (D-SNP)	03/01/2024
G2159 B-Hemolytic Streptococcus Testing: Effective Date: 03/01/2024	Ohio Dual Special Needs (D-SNP)	03/01/2024
M2112 Nerve Fiber Density Testing: Effective Date: 03/01/2024	Ohio Dual Special Needs (D-SNP)	03/01/2024
G2002 Cervical Cancer Screening:	Ohio Marketplace	03/01/2024
Effective Date: 03/01/2024		3,0 1,202 1
G2007 Prostate Biopsy Specimen Analysis: Effective Date: 3/01/2024	Ohio Marketplace	03/01/2024
G2036 Hepatitis Testing: Effective Date: 03/01/2024	Ohio Marketplace	03/01/2024
G2043 Celiac Disease Testing: Effective Date: 03/01/2024	Ohio Marketplace	03/01/2024

G2048 Biochemical Markers of Alzheimer Disease and Dementia:	Ohio Marketplace	03/01/2024
Effective Date: 03/01/2024		
G2051 Bone Turnover Markers	Ohio Marketplace	03/01/2024
Testing: Effective Date: 03/01/2024		00/04/0004
G2059 Epithelial Cell Cytology in	Ohio Marketplace	03/01/2024
Breast Cancer Risk Assessment:		
Effective Date: 03/01/2024	Obje Mankatole as	00/04/0004
G2060 Fecal Analysis in The	Ohio Marketplace	03/01/2024
Diagnosis of Intestinal Dysbiosis and Fecal Microbiota Transplant		
Testing: Effective Date: 03/01/2024		
G2061 Fecal Calprotectin Testing:	Ohio Marketplace	03/01/2024
Effective Date: 03/01/2024	Ono Marketplace	03/01/2024
G2098 Immune Cell Function	Ohio Marketplace	03/01/2024
Assay: Effective Date: 03/01/2024	One Marketplace	00/01/2021
G2100 In Vitro Chemoresistance	Ohio Marketplace	03/01/2024
and Chemosensitivity Assays	Ome manesplace	373 17232 1
G2105 Immunopharmacologic	Ohio Marketplace	03/01/2024
Monitoring of Therapeutic Serum		
Antibodies: Effective Date:		
03/01/2024		
G2107 Measurement of	Ohio Marketplace	03/01/2024
Thromboxane Metabolites for ASA	·	
Resistance: Effective Date:		
03/01/2024		
G2110 Serum Testing for Hepatic	Ohio Marketplace	03/01/2024
Fibrosis in the Evaluation and		
Monitoring of Chronic Liver		
Disease: Effective Date:		
03/01/2024	Obje Mankatole as	02/04/2024
G2115 Metabolite Markers for	Ohio Marketplace	03/01/2024
Thiopurines Testing: Effective Date: 03/01/2024		
G2119 Diagnostic Testing of	Ohio Marketplace	03/01/2024
Influenza: Effective Date:	Ono Marketplace	03/01/2024
03/01/2024		
G2121 Laboratory Testing for the	Ohio Marketplace	03/01/2024
Diagnosis of Inflammatory Bowel	One warketplace	00/01/2021
Disease: Effective Date:		
03/01/2024		
G2123 Serum Biomarker Testing	Ohio Marketplace	03/01/2024
for Multiple Sclerosis and Related		
Neurologic Diseases: Effective		
Date: 03/01/2024		
G2150 Biomarkers for Myocardial	Ohio Marketplace	03/01/2024
Infarction and Chronic Heart		
Failure: Effective Date: 03/01/2024		
G2157 Diagnostic Testing of	Ohio Marketplace	03/01/2024
Common Sexually Transmitted		
Infections: Effective Date:		
03/01/2024	Ohio Mayleatul	02/04/2024
G2159 B-Hemolytic Streptococcus	Ohio Marketplace	03/01/2024
Testing: Effective Date: 03/01/2024		

M2112 Nerve Fiber Density Testing: Effective Date: 03/01/2024	Ohio Marketplace	03/01/2024
G2002 Cervical Cancer Screening: Effective Date: 03/01/2024	Georgia Marketplace	03/01/2024
G2007 Prostate Biopsy Specimen Analysis: Effective Date: 3/01/2024	Georgia Marketplace	03/01/2024
G2036 Hepatitis Testing: Effective Date: 03/01/2024	Georgia Marketplace	03/01/2024
G2043 Celiac Disease Testing: Effective Date: 03/01/2024	Georgia Marketplace	03/01/2024
G2048 Biochemical Markers of Alzheimer Disease and Dementia: Effective Date: 03/01/2024	Georgia Marketplace	03/01/2024
G2051 Bone Turnover Markers Testing: Effective Date: 03/01/2024	Georgia Marketplace	03/01/2024
G2059 Epithelial Cell Cytology in Breast Cancer Risk Assessment: Effective Date: 03/01/2024	Georgia Marketplace	03/01/2024
G2060 Fecal Analysis in The Diagnosis of Intestinal Dysbiosis and Fecal Microbiota Transplant Testing: Effective Date: 03/01/2024	Georgia Marketplace	03/01/2024
G2061 Fecal Calprotectin Testing: Effective Date: 03/01/2024	Georgia Marketplace	03/01/2024
G2098 Immune Cell Function Assay: Effective Date: 03/01/2024	Georgia Marketplace	03/01/2024
G2100 In Vitro Chemoresistance and Chemosensitivity Assays	Georgia Marketplace	03/01/2024
G2105 Immunopharmacologic Monitoring of Therapeutic Serum Antibodies: Effective Date: 03/01/2024	Georgia Marketplace	03/01/2024
G2107 Measurement of Thromboxane Metabolites for ASA Resistance: Effective Date: 03/01/2024	Georgia Marketplace	03/01/2024
G2110 Serum Testing for Hepatic Fibrosis in the Evaluation and Monitoring of Chronic Liver Disease: Effective Date: 03/01/2024	Georgia Marketplace	03/01/2024
G2115 Metabolite Markers for Thiopurines Testing: Effective Date: 03/01/2024	Georgia Marketplace	03/01/2024
G2119 Diagnostic Testing of Influenza: Effective Date: 03/01/2024	Georgia Marketplace	03/01/2024
G2121 Laboratory Testing for the Diagnosis of Inflammatory Bowel Disease: Effective Date: 03/01/2024	Georgia Marketplace	03/01/2024

G2123 Serum Biomarker Testing for Multiple Sclerosis and Related Neurologic Diseases: Effective Date: 03/01/2024	Georgia Marketplace	03/01/2024
G2150 Biomarkers for Myocardial Infarction and Chronic Heart Failure: Effective Date: 03/01/2024	Georgia Marketplace	03/01/2024
G2157 Diagnostic Testing of Common Sexually Transmitted Infections: Effective Date: 03/01/2024	Georgia Marketplace	03/01/2024
G2159 B-Hemolytic Streptococcus Testing: Effective Date: 03/01/2024	Georgia Marketplace	03/01/2024
M2112 Nerve Fiber Density Testing: Effective Date: 03/01/2024	Georgia Marketplace	03/01/2024
G2002 Cervical Cancer Screening: Effective Date: 03/01/2024	Georgia Dual Special Needs (D-SNP)	03/01/2024
G2007 Prostate Biopsy Specimen Analysis: Effective Date: 3/01/2024	Georgia Dual Special Needs (D-SNP)	03/01/2024
G2036 Hepatitis Testing: Effective Date: 03/01/2024	Georgia Dual Special Needs (D-SNP)	03/01/2024
G2043 Celiac Disease Testing: Effective Date: 03/01/2024	Georgia Dual Special Needs (D-SNP)	03/01/2024
G2048 Biochemical Markers of Alzheimer Disease and Dementia: Effective Date: 03/01/2024	Georgia Dual Special Needs (D-SNP)	03/01/2024
G2051 Bone Turnover Markers Testing: Effective Date: 03/01/2024	Georgia Dual Special Needs (D-SNP)	03/01/2024
G2059 Epithelial Cell Cytology in Breast Cancer Risk Assessment: Effective Date: 03/01/2024	Georgia Dual Special Needs (D-SNP)	03/01/2024
G2060 Fecal Analysis in The Diagnosis of Intestinal Dysbiosis and Fecal Microbiota Transplant Testing: Effective Date: 03/01/2024	Georgia Dual Special Needs (D-SNP)	03/01/2024
G2061 Fecal Calprotectin Testing: Effective Date: 03/01/2024	Georgia Dual Special Needs (D-SNP)	03/01/2024
G2098 Immune Cell Function Assay: Effective Date: 03/01/2024	Georgia Dual Special Needs (D-SNP)	03/01/2024
G2100 In Vitro Chemoresistance and Chemosensitivity Assays	Georgia Dual Special Needs (D-SNP)	03/01/2024
G2105 Immunopharmacologic Monitoring of Therapeutic Serum Antibodies: Effective Date: 03/01/2024	Georgia Dual Special Needs (D-SNP)	03/01/2024
G2107 Measurement of Thromboxane Metabolites for ASA Resistance: Effective Date: 03/01/2024	Georgia Dual Special Needs (D-SNP)	03/01/2024
G2110 Serum Testing for Hepatic Fibrosis in the Evaluation and Monitoring of Chronic Liver	Georgia Dual Special Needs (D-SNP)	03/01/2024

	1	
Disease: Effective Date: 03/01/2024		
G2115 Metabolite Markers for	Georgia Dual Special Needs (D-SNP)	03/01/2024
Thiopurines Testing: Effective	Georgia Duai Speciai Needs (D-SNF)	03/01/2024
Date: 03/01/2024		
G2119 Diagnostic Testing of	Georgia Dual Special Needs (D-SNP)	03/01/2024
Influenza: Effective Date:	Georgia Duai Speciai Needs (D-SNP)	03/01/2024
03/01/2024		
	Coordia Dual Cresial Monda (D. CMD)	03/01/2024
G2121 Laboratory Testing for the Diagnosis of Inflammatory Bowel	Georgia Dual Special Needs (D-SNP)	03/01/2024
Disease: Effective Date:		
03/01/2024		
	Coordia Dual Cresial Monda (D. CMD)	03/01/2024
G2123 Serum Biomarker Testing	Georgia Dual Special Needs (D-SNP)	03/01/2024
for Multiple Sclerosis and Related		
Neurologic Diseases: Effective		
Date: 03/01/2024	Coordia Dual Chasial Manda (D. CMD)	03/01/2024
G2150 Biomarkers for Myocardial Infarction and Chronic Heart	Georgia Dual Special Needs (D-SNP)	03/01/2024
_		
Failure: Effective Date: 03/01/2024	Coordia Dual Special Manda (D. CMD)	02/01/2024
G2157 Diagnostic Testing of Common Sexually Transmitted	Georgia Dual Special Needs (D-SNP)	03/01/2024
Infections: Effective Date:		
03/01/2024	Coordia Dual Crasial Naceda (D. CND)	02/04/2024
G2159 B-Hemolytic Streptococcus	Georgia Dual Special Needs (D-SNP)	03/01/2024
Testing: Effective Date: 03/01/2024 M2112 Nerve Fiber Density	Georgia Dual Special Needs (D-SNP)	03/01/2024
	Georgia Duai Speciai Needs (D-SNP)	03/01/2024
Testing: Effective Date: 03/01/2024	1	
Testing: Effective Date: 03/01/2024		
Testing: Effective Date: 03/01/2024  G2002 Cervical Cancer Screening:	Kentucky Marketplace	03/01/2024
	Kentucky Marketplace	03/01/2024
G2002 Cervical Cancer Screening:	Kentucky Marketplace  Kentucky Marketplace	03/01/2024
G2002 Cervical Cancer Screening: Effective Date: 03/01/2024	·	
G2002 Cervical Cancer Screening: Effective Date: 03/01/2024 G2007 Prostate Biopsy Specimen	·	
G2002 Cervical Cancer Screening: Effective Date: 03/01/2024 G2007 Prostate Biopsy Specimen Analysis: Effective Date: 3/01/2024 G2036 Hepatitis Testing: Effective Date: 03/01/2024	Kentucky Marketplace  Kentucky Marketplace	03/01/2024
G2002 Cervical Cancer Screening: Effective Date: 03/01/2024 G2007 Prostate Biopsy Specimen Analysis: Effective Date: 3/01/2024 G2036 Hepatitis Testing: Effective	Kentucky Marketplace	03/01/2024
G2002 Cervical Cancer Screening: Effective Date: 03/01/2024 G2007 Prostate Biopsy Specimen Analysis: Effective Date: 3/01/2024 G2036 Hepatitis Testing: Effective Date: 03/01/2024 G2043 Celiac Disease Testing: Effective Date: 03/01/2024	Kentucky Marketplace  Kentucky Marketplace	03/01/2024
G2002 Cervical Cancer Screening: Effective Date: 03/01/2024 G2007 Prostate Biopsy Specimen Analysis: Effective Date: 3/01/2024 G2036 Hepatitis Testing: Effective Date: 03/01/2024 G2043 Celiac Disease Testing:	Kentucky Marketplace  Kentucky Marketplace	03/01/2024
G2002 Cervical Cancer Screening: Effective Date: 03/01/2024 G2007 Prostate Biopsy Specimen Analysis: Effective Date: 3/01/2024 G2036 Hepatitis Testing: Effective Date: 03/01/2024 G2043 Celiac Disease Testing: Effective Date: 03/01/2024 G2048 Biochemical Markers of Alzheimer Disease and Dementia:	Kentucky Marketplace  Kentucky Marketplace  Kentucky Marketplace	03/01/2024 03/01/2024 03/01/2024
G2002 Cervical Cancer Screening: Effective Date: 03/01/2024 G2007 Prostate Biopsy Specimen Analysis: Effective Date: 3/01/2024 G2036 Hepatitis Testing: Effective Date: 03/01/2024 G2043 Celiac Disease Testing: Effective Date: 03/01/2024 G2048 Biochemical Markers of Alzheimer Disease and Dementia: Effective Date: 03/01/2024	Kentucky Marketplace  Kentucky Marketplace  Kentucky Marketplace  Kentucky Marketplace	03/01/2024 03/01/2024 03/01/2024 03/01/2024
G2002 Cervical Cancer Screening: Effective Date: 03/01/2024 G2007 Prostate Biopsy Specimen Analysis: Effective Date: 3/01/2024 G2036 Hepatitis Testing: Effective Date: 03/01/2024 G2043 Celiac Disease Testing: Effective Date: 03/01/2024 G2048 Biochemical Markers of Alzheimer Disease and Dementia: Effective Date: 03/01/2024 G2051 Bone Turnover Markers	Kentucky Marketplace  Kentucky Marketplace  Kentucky Marketplace	03/01/2024 03/01/2024 03/01/2024
G2002 Cervical Cancer Screening: Effective Date: 03/01/2024 G2007 Prostate Biopsy Specimen Analysis: Effective Date: 3/01/2024 G2036 Hepatitis Testing: Effective Date: 03/01/2024 G2043 Celiac Disease Testing: Effective Date: 03/01/2024 G2048 Biochemical Markers of Alzheimer Disease and Dementia: Effective Date: 03/01/2024 G2051 Bone Turnover Markers Testing: Effective Date: 03/01/2024	Kentucky Marketplace  Kentucky Marketplace  Kentucky Marketplace  Kentucky Marketplace  Kentucky Marketplace	03/01/2024 03/01/2024 03/01/2024 03/01/2024 03/01/2024
G2002 Cervical Cancer Screening: Effective Date: 03/01/2024 G2007 Prostate Biopsy Specimen Analysis: Effective Date: 3/01/2024 G2036 Hepatitis Testing: Effective Date: 03/01/2024 G2043 Celiac Disease Testing: Effective Date: 03/01/2024 G2048 Biochemical Markers of Alzheimer Disease and Dementia: Effective Date: 03/01/2024 G2051 Bone Turnover Markers Testing: Effective Date: 03/01/2024 G2059 Epithelial Cell Cytology in	Kentucky Marketplace  Kentucky Marketplace  Kentucky Marketplace  Kentucky Marketplace	03/01/2024 03/01/2024 03/01/2024 03/01/2024
G2002 Cervical Cancer Screening: Effective Date: 03/01/2024 G2007 Prostate Biopsy Specimen Analysis: Effective Date: 3/01/2024 G2036 Hepatitis Testing: Effective Date: 03/01/2024 G2043 Celiac Disease Testing: Effective Date: 03/01/2024 G2048 Biochemical Markers of Alzheimer Disease and Dementia: Effective Date: 03/01/2024 G2051 Bone Turnover Markers Testing: Effective Date: 03/01/2024 G2059 Epithelial Cell Cytology in Breast Cancer Risk Assessment:	Kentucky Marketplace  Kentucky Marketplace  Kentucky Marketplace  Kentucky Marketplace  Kentucky Marketplace	03/01/2024 03/01/2024 03/01/2024 03/01/2024 03/01/2024
G2002 Cervical Cancer Screening: Effective Date: 03/01/2024 G2007 Prostate Biopsy Specimen Analysis: Effective Date: 3/01/2024 G2036 Hepatitis Testing: Effective Date: 03/01/2024 G2043 Celiac Disease Testing: Effective Date: 03/01/2024 G2048 Biochemical Markers of Alzheimer Disease and Dementia: Effective Date: 03/01/2024 G2051 Bone Turnover Markers Testing: Effective Date: 03/01/2024 G2059 Epithelial Cell Cytology in Breast Cancer Risk Assessment: Effective Date: 03/01/2024	Kentucky Marketplace  Kentucky Marketplace  Kentucky Marketplace  Kentucky Marketplace  Kentucky Marketplace  Kentucky Marketplace	03/01/2024 03/01/2024 03/01/2024 03/01/2024 03/01/2024 03/01/2024
G2002 Cervical Cancer Screening: Effective Date: 03/01/2024 G2007 Prostate Biopsy Specimen Analysis: Effective Date: 3/01/2024 G2036 Hepatitis Testing: Effective Date: 03/01/2024 G2043 Celiac Disease Testing: Effective Date: 03/01/2024 G2048 Biochemical Markers of Alzheimer Disease and Dementia: Effective Date: 03/01/2024 G2051 Bone Turnover Markers Testing: Effective Date: 03/01/2024 G2059 Epithelial Cell Cytology in Breast Cancer Risk Assessment: Effective Date: 03/01/2024 G2060 Fecal Analysis in The	Kentucky Marketplace  Kentucky Marketplace  Kentucky Marketplace  Kentucky Marketplace  Kentucky Marketplace	03/01/2024 03/01/2024 03/01/2024 03/01/2024 03/01/2024
G2002 Cervical Cancer Screening: Effective Date: 03/01/2024 G2007 Prostate Biopsy Specimen Analysis: Effective Date: 3/01/2024 G2036 Hepatitis Testing: Effective Date: 03/01/2024 G2043 Celiac Disease Testing: Effective Date: 03/01/2024 G2048 Biochemical Markers of Alzheimer Disease and Dementia: Effective Date: 03/01/2024 G2051 Bone Turnover Markers Testing: Effective Date: 03/01/2024 G2059 Epithelial Cell Cytology in Breast Cancer Risk Assessment: Effective Date: 03/01/2024 G2060 Fecal Analysis in The Diagnosis of Intestinal Dysbiosis	Kentucky Marketplace  Kentucky Marketplace  Kentucky Marketplace  Kentucky Marketplace  Kentucky Marketplace  Kentucky Marketplace	03/01/2024 03/01/2024 03/01/2024 03/01/2024 03/01/2024 03/01/2024
G2002 Cervical Cancer Screening: Effective Date: 03/01/2024 G2007 Prostate Biopsy Specimen Analysis: Effective Date: 3/01/2024 G2036 Hepatitis Testing: Effective Date: 03/01/2024 G2043 Celiac Disease Testing: Effective Date: 03/01/2024 G2048 Biochemical Markers of Alzheimer Disease and Dementia: Effective Date: 03/01/2024 G2051 Bone Turnover Markers Testing: Effective Date: 03/01/2024 G2059 Epithelial Cell Cytology in Breast Cancer Risk Assessment: Effective Date: 03/01/2024 G2060 Fecal Analysis in The Diagnosis of Intestinal Dysbiosis and Fecal Microbiota Transplant	Kentucky Marketplace  Kentucky Marketplace  Kentucky Marketplace  Kentucky Marketplace  Kentucky Marketplace  Kentucky Marketplace	03/01/2024 03/01/2024 03/01/2024 03/01/2024 03/01/2024 03/01/2024
G2002 Cervical Cancer Screening: Effective Date: 03/01/2024 G2007 Prostate Biopsy Specimen Analysis: Effective Date: 3/01/2024 G2036 Hepatitis Testing: Effective Date: 03/01/2024 G2043 Celiac Disease Testing: Effective Date: 03/01/2024 G2048 Biochemical Markers of Alzheimer Disease and Dementia: Effective Date: 03/01/2024 G2051 Bone Turnover Markers Testing: Effective Date: 03/01/2024 G2059 Epithelial Cell Cytology in Breast Cancer Risk Assessment: Effective Date: 03/01/2024 G2060 Fecal Analysis in The Diagnosis of Intestinal Dysbiosis and Fecal Microbiota Transplant Testing: Effective Date: 03/01/2024	Kentucky Marketplace	03/01/2024 03/01/2024 03/01/2024 03/01/2024 03/01/2024 03/01/2024
G2002 Cervical Cancer Screening: Effective Date: 03/01/2024 G2007 Prostate Biopsy Specimen Analysis: Effective Date: 3/01/2024 G2036 Hepatitis Testing: Effective Date: 03/01/2024 G2043 Celiac Disease Testing: Effective Date: 03/01/2024 G2048 Biochemical Markers of Alzheimer Disease and Dementia: Effective Date: 03/01/2024 G2051 Bone Turnover Markers Testing: Effective Date: 03/01/2024 G2059 Epithelial Cell Cytology in Breast Cancer Risk Assessment: Effective Date: 03/01/2024 G2060 Fecal Analysis in The Diagnosis of Intestinal Dysbiosis and Fecal Microbiota Transplant	Kentucky Marketplace  Kentucky Marketplace  Kentucky Marketplace  Kentucky Marketplace  Kentucky Marketplace  Kentucky Marketplace	03/01/2024 03/01/2024 03/01/2024 03/01/2024 03/01/2024 03/01/2024
G2002 Cervical Cancer Screening: Effective Date: 03/01/2024 G2007 Prostate Biopsy Specimen Analysis: Effective Date: 3/01/2024 G2036 Hepatitis Testing: Effective Date: 03/01/2024 G2043 Celiac Disease Testing: Effective Date: 03/01/2024 G2048 Biochemical Markers of Alzheimer Disease and Dementia: Effective Date: 03/01/2024 G2051 Bone Turnover Markers Testing: Effective Date: 03/01/2024 G2059 Epithelial Cell Cytology in Breast Cancer Risk Assessment: Effective Date: 03/01/2024 G2060 Fecal Analysis in The Diagnosis of Intestinal Dysbiosis and Fecal Microbiota Transplant Testing: Effective Date: 03/01/2024 G2061 Fecal Calprotectin Testing: Effective Date: 03/01/2024	Kentucky Marketplace	03/01/2024 03/01/2024 03/01/2024 03/01/2024 03/01/2024 03/01/2024 03/01/2024
G2002 Cervical Cancer Screening: Effective Date: 03/01/2024 G2007 Prostate Biopsy Specimen Analysis: Effective Date: 3/01/2024 G2036 Hepatitis Testing: Effective Date: 03/01/2024 G2043 Celiac Disease Testing: Effective Date: 03/01/2024 G2048 Biochemical Markers of Alzheimer Disease and Dementia: Effective Date: 03/01/2024 G2051 Bone Turnover Markers Testing: Effective Date: 03/01/2024 G2059 Epithelial Cell Cytology in Breast Cancer Risk Assessment: Effective Date: 03/01/2024 G2060 Fecal Analysis in The Diagnosis of Intestinal Dysbiosis and Fecal Microbiota Transplant Testing: Effective Date: 03/01/2024 G2061 Fecal Calprotectin Testing:	Kentucky Marketplace	03/01/2024 03/01/2024 03/01/2024 03/01/2024 03/01/2024 03/01/2024

C2100 In Vitra Chamarasiatanas	Mantala Mantatala a	02/04/2024
G2100 In Vitro Chemoresistance	Kentucky Marketplace	03/01/2024
and Chemosensitivity Assays	Manhualu Mankahalaa	02/04/2024
G2105 Immunopharmacologic	Kentucky Marketplace	03/01/2024
Monitoring of Therapeutic Serum Antibodies: Effective Date:		
03/01/2024	Mantuals: Mantatalaaa	02/04/2024
G2107 Measurement of Thromboxane Metabolites for ASA	Kentucky Marketplace	03/01/2024
Resistance: Effective Date:		
03/01/2024		
G2110 Serum Testing for Hepatic	Kentucky Marketplace	03/01/2024
Fibrosis in the Evaluation and	Nentucky Marketplace	03/01/2024
Monitoring of Chronic Liver		
Disease: Effective Date:		
03/01/2024		
G2115 Metabolite Markers for	Kentucky Marketplace	03/01/2024
Thiopurines Testing: Effective	Transity Markotpiaco	33/31/2327
Date: 03/01/2024		
G2119 Diagnostic Testing of	Kentucky Marketplace	03/01/2024
Influenza: Effective Date:		1 2,3 ., 202 .
03/01/2024		
G2121 Laboratory Testing for the	Kentucky Marketplace	03/01/2024
Diagnosis of Inflammatory Bowel		
Disease: Effective Date:		
03/01/2024		
G2123 Serum Biomarker Testing	Kentucky Marketplace	03/01/2024
for Multiple Sclerosis and Related	·	
Neurologic Diseases: Effective		
Date: 03/01/2024		
G2150 Biomarkers for Myocardial	Kentucky Marketplace	03/01/2024
Infarction and Chronic Heart		
Failure: Effective Date: 03/01/2024		
G2157 Diagnostic Testing of	Kentucky Marketplace	03/01/2024
Common Sexually Transmitted		
Infections: Effective Date:		
03/01/2024		
G2159 B-Hemolytic Streptococcus	Kentucky Marketplace	03/01/2024
Testing: Effective Date: 03/01/2024		00/04/0534
M2112 Nerve Fiber Density	Kentucky Marketplace	03/01/2024
Testing: Effective Date: 03/01/2024		
C2002 Comical Caraca Caraca	Nouth Canalina Mantatula	02/04/2024
G2002 Cervical Cancer Screening:	North Carolina Marketplace	03/01/2024
Effective Date: 03/01/2024	North Carolina Martistales	02/04/2024
G2007 Prostate Biopsy Specimen	North Carolina Marketplace	03/01/2024
Analysis: Effective Date: 3/01/2024	North Carolina Markatalasa	02/04/2024
G2036 Hepatitis Testing: Effective	North Carolina Marketplace	03/01/2024
Date: 03/01/2024	North Carolina Markatalasa	02/04/2024
G2043 Celiac Disease Testing: Effective Date: 03/01/2024	North Carolina Marketplace	03/01/2024
G2048 Biochemical Markers of	North Carolina Marketplace	03/01/2024
Alzheimer Disease and Dementia:	Notifi Catolilla Warketplace	03/01/2024
Effective Date: 03/01/2024		
LITECTIVE Date. 03/01/2024		

	T	
G2051 Bone Turnover Markers Testing: Effective Date: 03/01/2024	North Carolina Marketplace	03/01/2024
G2059 Epithelial Cell Cytology in	North Carolina Marketplace	03/01/2024
Breast Cancer Risk Assessment:	Trotal Garonia Markotplaco	00/01/2021
Effective Date: 03/01/2024		
G2060 Fecal Analysis in The	North Carolina Marketplace	03/01/2024
Diagnosis of Intestinal Dysbiosis	Trotal Garolina Markotplaco	00/01/2021
and Fecal Microbiota Transplant		
Testing: Effective Date: 03/01/2024		
G2061 Fecal Calprotectin Testing:	North Carolina Marketplace	03/01/2024
Effective Date: 03/01/2024	Trorur Garonna marriotpiaes	00/01/2021
G2098 Immune Cell Function	North Carolina Marketplace	03/01/2024
Assay: Effective Date: 03/01/2024	, , , , , , , , , , , , , , , , , , ,	33.3 ., 232 .
G2100 In Vitro Chemoresistance	North Carolina Marketplace	03/01/2024
and Chemosensitivity Assays	, , , , , , , , , , , , , , , , , , ,	33.3 ., 232 .
G2105 Immunopharmacologic	North Carolina Marketplace	03/01/2024
Monitoring of Therapeutic Serum	Trorur Garonna marriotpiaes	00/01/2021
Antibodies: Effective Date:		
03/01/2024		
G2107 Measurement of	North Carolina Marketplace	03/01/2024
Thromboxane Metabolites for ASA		
Resistance: Effective Date:		
03/01/2024		
G2110 Serum Testing for Hepatic	North Carolina Marketplace	03/01/2024
Fibrosis in the Evaluation and	1	
Monitoring of Chronic Liver		
Disease: Effective Date:		
03/01/2024		
G2115 Metabolite Markers for	North Carolina Marketplace	03/01/2024
Thiopurines Testing: Effective	·	
Date: 03/01/2024		
G2119 Diagnostic Testing of	North Carolina Marketplace	03/01/2024
Influenza: Effective Date:		
03/01/2024		
G2121 Laboratory Testing for the	North Carolina Marketplace	03/01/2024
Diagnosis of Inflammatory Bowel		
Disease: Effective Date:		
03/01/2024		
G2123 Serum Biomarker Testing	North Carolina Marketplace	03/01/2024
for Multiple Sclerosis and Related		
Neurologic Diseases: Effective		
Date: 03/01/2024		00/04/0004
G2150 Biomarkers for Myocardial	North Carolina Marketplace	03/01/2024
Infarction and Chronic Heart		
Failure: Effective Date: 03/01/2024	Namba Canalina Mantatalaa	02/04/2024
G2157 Diagnostic Testing of	North Carolina Marketplace	03/01/2024
Common Sexually Transmitted		
Infections: Effective Date:		
03/01/2024	North Carolina Marketalasa	02/04/2024
G2159 B-Hemolytic Streptococcus	North Carolina Marketplace	03/01/2024
Testing: Effective Date: 03/01/2024 M2112 Nerve Fiber Density	North Carolina Marketalana	03/01/2024
Testing: Effective Date: 03/01/2024	North Carolina Marketplace	03/01/2024
resultg. Elicotive Date. 03/01/2024		

G2002 Cervical Cancer Screening: Effective Date: 03/01/2024	West Virginia Marketplace	03/01/2024
G2007 Prostate Biopsy Specimen Analysis: Effective Date: 3/01/2024	West Virginia Marketplace	03/01/2024
G2036 Hepatitis Testing: Effective Date: 03/01/2024	West Virginia Marketplace	03/01/2024
G2043 Celiac Disease Testing: Effective Date: 03/01/2024	West Virginia Marketplace	03/01/2024
G2048 Biochemical Markers of Alzheimer Disease and Dementia: Effective Date: 03/01/2024	West Virginia Marketplace	03/01/2024
G2051 Bone Turnover Markers Testing: Effective Date: 03/01/2024	West Virginia Marketplace	03/01/2024
G2059 Epithelial Cell Cytology in Breast Cancer Risk Assessment: Effective Date: 03/01/2024	West Virginia Marketplace	03/01/2024
G2060 Fecal Analysis in The Diagnosis of Intestinal Dysbiosis and Fecal Microbiota Transplant Testing: Effective Date: 03/01/2024	West Virginia Marketplace	03/01/2024
G2061 Fecal Calprotectin Testing: Effective Date: 03/01/2024	West Virginia Marketplace	03/01/2024
G2098 Immune Cell Function Assay: Effective Date: 03/01/2024	West Virginia Marketplace	03/01/2024
G2100 In Vitro Chemoresistance and Chemosensitivity Assays	West Virginia Marketplace	03/01/2024
G2105 Immunopharmacologic Monitoring of Therapeutic Serum Antibodies: Effective Date: 03/01/2024	West Virginia Marketplace	03/01/2024
G2107 Measurement of Thromboxane Metabolites for ASA Resistance: Effective Date: 03/01/2024	West Virginia Marketplace	03/01/2024
G2110 Serum Testing for Hepatic Fibrosis in the Evaluation and Monitoring of Chronic Liver Disease: Effective Date: 03/01/2024	West Virginia Marketplace	03/01/2024
G2115 Metabolite Markers for Thiopurines Testing: Effective Date: 03/01/2024	West Virginia Marketplace	03/01/2024
G2119 Diagnostic Testing of Influenza: Effective Date: 03/01/2024	West Virginia Marketplace	03/01/2024
G2121 Laboratory Testing for the Diagnosis of Inflammatory Bowel Disease: Effective Date: 03/01/2024	West Virginia Marketplace	03/01/2024
G2123 Serum Biomarker Testing for Multiple Sclerosis and Related Neurologic Diseases: Effective Date: 03/01/2024	West Virginia Marketplace	03/01/2024

G2150 Biomarkers for Myocardial Infarction and Chronic Heart	West Virginia Marketplace	12/01/2023
Failure: Effective Date: 03/01/2024		
G2157 Diagnostic Testing of	West Virginia Marketplace	12/01/2023
Common Sexually Transmitted		
Infections: Effective Date:		
03/01/2024		
G2159 B-Hemolytic Streptococcus	West Virginia Marketplace	03/01/2024
Testing: Effective Date: 03/01/2024		
M2112 Nerve Fiber Density	West Virginia Marketplace	03/01/2024
Testing: Effective Date: 03/01/2024		

## **Trial Claim Advice Tool**

Providers may use the Trial Claim Advice tool to review claims with laboratory services for adherence and consistency with CareSource laboratory policies. This is a simulation tool and does not guarantee approval or reimbursement of claims. You can access the Trial Claim Advice Tool on the CareSource <a href="Provider Portal">Provider Portal</a>.

Multi-Multi-P-2589252